Market Overview

My goal is to be on stage with my computer and let you
see my screen and make sure you know what buttons to
press, where you’re getting in & out, how to calculate
risk, your targets — all of those things.
It’s real-life trading. Make sure you sign up!
- Jerremy Newsome
GET TICKETS

Clovis Oncology Falls 8%: Here's What You Need To Know

Share:
Clovis Oncology Falls 8%: Here's What You Need To Know

Shares of Clovis Oncology Inc (NASDAQ: CLVS) lost more than 8 percent on Friday after the company confirmed that the FDA posted briefing documents ahead of the Oncologic Drugs Advisory Committee (ODAC) meeting to discuss accelerated approval of the New Drug Application (NDA) for rociletinib.

The FDA recommended in its briefing documents the inclusion of a boxed warning on Clovis' drug, rociletinib.

"FDA recommends the inclusion of a Boxed Warning for the risk of QTc prolongation leading to Torsades de pointes," the FDA said in its document. "FDA also recommends that labeling describe ECG monitoring of QTc interval at baseline and periodically while receiving treatment with rociletinib. FDA also recommends inclusion in labeling of Warning and Precautions subsections for QTc prolongation, hyperglycemia, interstitial ling disease/pneumonitis, pancreatitis, and cataracts."

Related Link: VRX Memo: Addyis Third-Party Sales Force To Be Cut When Contract Ends April 15, Planning Sales Effort Re-Launch

The Street's biotech expert, Adam Feuerstein stated that the FDA's briefing documents "confirms – and amplifies – all the bad stuff we knew about the drug already," including the company misleading investors about the drug's benefit to risk profile.

"Clovis now says the confirmed response rates to the 500 mg and 625 mg doses of rociletinib are 28 percent and 34 percent, respectively," Feuerstein argued in late 2015. "Those are lower than the response rates previously disclosed by Clovis."

Feuerstein also suggested that Clovis may actually be "better off" if the FDA rejects the drug.

Image Credit: Public Domain

Posted-In: Analyst Color Biotech News Health Care FDA Movers Trading Ideas General Best of Benzinga

 

Related Articles (CLVS)

View Comments and Join the Discussion!

Latest Ratings

StockFirmActionPT
MCDMaintains200.0
AVGOMaintains300.0
AVGOMaintains315.0
CASYMaintains152.0
MRKMaintains93.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Trading Daily
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com

Report: Ameren, Canadian Funds Interested In Westar

UPDATE: Ides Capital Letter to Boingo Board